Benitec Biopharma (BNTC) Common Equity (2019 - 2025)

Benitec Biopharma (BNTC) has 7 years of Common Equity data on file, last reported at $187.4 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 27332.7% year-over-year to $187.4 million; the trailing twelve-month figure through Dec 2025 stood at $187.4 million (up 27332.7% YoY), and the FY2025 full-year result was $97.3 million, up 105.92% from the prior year.
• Common Equity improved to $187.4 million in Q4 2025, from $93.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $260.5 million in Q3 2024 to a low of -$219.4 million in Q1 2025.
• A 5-year average of $30.6 million and a median of $13.1 million in 2022 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 27332.7% in 2025, while the deepest fall reached 2007.57% in 2025.
• Tracing BNTC's Common Equity over 5 years: stood at $10.8 million in 2021, then fell by 17.0% to $9.0 million in 2022, then jumped by 72.0% to $15.5 million in 2023, then slumped by 104.45% to -$688000.0 in 2024, then jumped by 27332.7% to $187.4 million in 2025.
• Business Quant data shows BNTC's Common Equity at $187.4 million in Q4 2025, $93.6 million in Q3 2025, and $97.3 million in Q2 2025.